«

»

Why Medicare’s Aduhelm Coverage Decision Could Increase Pressure on Officials to Roll Back the Record Part B Premium Increase for 2022

In a new Policy Watch, KFF experts explain why Medicare’s preliminary decision to cover a new Alzheimer’s drug only for a limited group of beneficiaries is likely to intensify pressure on officials to reconsider the increase in the Medicare Part B premium for 2022. Earlier this week, CMS issued a preliminary National Coverage Determination that…More

Read the full post at Reports on Health Insurance and Health Care Costs from the Kaiser Family Foundation
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive